Thu, Nov 27, 2014, 3:59 PM EST - U.S. Markets closed for Thanksgiving Day


% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

  • iddoc60 iddoc60 Dec 16, 2012 1:56 PM Flag

    AF's bottom line argument basically is!

    Why bother treating the local tumor because you are going to have a distant met anyway and are going to die!

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • And our reply is what?

      • 2 Replies to golongin2008
      • bking73 Dec 16, 2012 2:25 PM Flag

        It is difficult to see FDA saying no to a treatment that shows huge efficacy delta in preventing LR but fares the same or not huge statistical difference in DR. As there will always be patients that may not have DR or get DR after many years, yielding significant survival benefits. That said, IF DR is not impacted by the Thermodox treatment, the SPA will likely read out as primary endpoint not met, a not so insignificant consideration for longs.

        All the more perplexing, why management did significant insider buying, conversion of warrants, no secondary decision before results etc.? Do they have a different take on Thermodox impact on DR that we are not aware of? Afterall we are betting some of our investment money, while they have bet their jobs and the very survival of the company on this outcome, and it would be unwise to think that they are looking at the same odds as we do, unless they are reckless gamblers.

      • 58 of 192 patients would have benefited (maybe cured) because of Thermadox: more than 25%, if you were diagnosed with HCC, wouldn't you hope to be in that group? What would stop FDA approval? There are no safety issues!

2.68+0.01(+0.37%)Nov 26 3:58 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.